Protagonist Therapeutics PTGX D&A

D&A at other companies

Bristol-Myers SquibbBMY

$594M-41.2%

Eli LillyLLY

$534M+11.7%

AmgenAMGN

$1.11B-17.1%

IncyteINCY

$26.48M+15.5%

Disc MedicineIRON

$89K+345%

Kymera TherapeuticsKYMR

$2.03M-2.6%

FAQ

What is Protagonist Therapeutics's D&A?

Protagonist Therapeutics (PTGX) reported D&A of $397K in Q2 2026.

How has Protagonist Therapeutics's D&A changed year-over-year?

Protagonist Therapeutics's D&A increased by 30.6% year-over-year, from $304K to $397K.

What is the long-term trend for Protagonist Therapeutics's D&A?

Over 4 years (2021 to 2025), Protagonist Therapeutics's D&A has grown at a 12.0% compound annual growth rate (CAGR), from $813K to $1.28M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.